Arcus Biosciences to Participate at Upcoming Virtual Investor Events

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in two virtual investor events in February 2023. The events include the SVB Securities Virtual Global Biopharma Conference on February 14 at 12:00 p.m. ET, and Citi’s 2023 Virtual Oncology Leadership Summit on February 21 at 1:00 p.m. ET. Both will feature fireside chats from the management team. Webcasts will be accessible through the “Investors & Media” section of the Arcus Biosciences website, with replays available post-event. The company is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events:

SVB Securities Virtual Global Biopharma Conference
Date: Tuesday, February 14^th, 2023
Time: 12:00 p.m. ET
Format: Fireside Chat

Citi’s 2023 Virtual Oncology Leadership Summit
Date: Tuesday, February 21, 2023
Time: 1:00 p.m. ET
Format: Fireside Chat

Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and A2a/A2b receptors) and HIF-2a. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005139/en/

Investor Inquiries

Pia Banerjee

Head of Investor Relations & Strategy

(617) 459-2006

pbanerjee@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

What investor events is Arcus Biosciences attending in February 2023?

Arcus Biosciences is attending the SVB Securities Virtual Global Biopharma Conference on February 14 and Citi’s 2023 Virtual Oncology Leadership Summit on February 21, 2023.

What time are the Arcus Biosciences investor events scheduled?

The SVB Securities event is at 12:00 p.m. ET, and Citi’s summit is at 1:00 p.m. ET.

How can I watch the Arcus Biosciences investor events?

The events will be available via live webcasts on the 'Investors & Media' section of the Arcus Biosciences website, with replays following the events.

What is the focus of Arcus Biosciences?

Arcus Biosciences focuses on developing differentiated molecules and combination therapies for cancer treatment.

When was Arcus Biosciences founded?

Arcus Biosciences was founded in 2015.